Health Canada Approves LEQEMBI for Early Alzheimer's Treatment
Eisai Co., Ltd. and Biogen Inc. announced that Health Canada has granted authorization for LEQEMBI (lecanemab) for the treatment of early Alzheimer's disease.
The approval is for adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease who are apolipoprotein E ε4 non-carriers or heterozygotes and have confirmed amyloid pathology.
LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease, to be authorized in Canada.
Author's summary: Eisai and Biogen's LEQEMBI approved in Canada.
More News
- Canada’s Lululemon Partners With National Football League
- 2 US Navy aircraft crash in South China Sea
- ACCC sues Microsoft over alleged misleading subscription practices in Australia
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Deadline is Dec. 31 to apply for Renew NC grants - Hendersonville Lightning
- BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine